Long-term Recurrence and Progression Patterns in a Contemporary Series of Patients with Carcinoma In Situ of the Bladder With or Without Associated Ta/T1 Disease Treated with Bacillus Calmette-Guérin: Implications for Risk-adapted Follow-up

Subiela, 2020, Carcinoma in situ of the urinary bladder: a systematic review of current knowledge regarding detection, treatment, and outcomes, Eur Urol Focus, 6, 674, 10.1016/j.euf.2019.03.012 Lamm, 1998, Updated concepts and treatment of carcinoma in situ, Urol Oncol, 4, 130, 10.1016/S1078-1439(99)00020-4 Jakse, 2001, Intravesical BCG in patients with carcinoma in situ of the urinary bladder: long-term results of EORTC GU Group phase II protocol 30861, Eur Urol, 40, 144, 10.1159/000049765 Lamm, 2000, Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study, J Urol, 163, 1124, 10.1016/S0022-5347(05)67707-5 Gofrit, 2009, The natural history of bladder carcinoma in situ after initial response to bacillus Calmette-Guerin immunotherapy, Urol Oncol, 27, 258, 10.1016/j.urolonc.2007.12.011 van Rhijn, 2012, A new and highly prognostic system to discern T1 bladder cancer substage, Eur Urol, 61, 378, 10.1016/j.eururo.2011.10.026 Gaya, 2012, A second transurethral resection could be not necessary in all high grade non-muscle-invasive bladder tumors, Actas Urol Esp, 36, 539, 10.1016/j.acuro.2012.03.011 Kamat, 2015, Expert consensus document: consensus statement on best practice management regarding the use of intravesical immunotherapy with BCG for bladder cancer, Nat Rev Urol, 12, 225, 10.1038/nrurol.2015.58 Subiela, 2022, Impact of clinical and pathological subtypes of carcinoma in situ (CIS) of the bladder: lessons learned from long-term follow-up of a series of CIS patients treated with BCG, Urol Oncol, 40, 9e1, 10.1016/j.urolonc.2021.05.006 US Food and Drug Administration, 2018 Brookhart, 2006, Variable selection for propensity score models, Am J Epidemiol, 163, 1149, 10.1093/aje/kwj149 Golabek, 2017, Is it possible to stop follow-up of patients with primary T1G3 urothelial carcinoma of the bladder managed with intravesical bacille Calmette-Guerin immunotherapy?, World J Urol, 35, 237, 10.1007/s00345-016-1856-9 Holmang, 2012, Should follow-up cystoscopy in bacillus Calmette-Guerin-treated patients continue after five tumour-free years?, Eur Urol, 61, 503, 10.1016/j.eururo.2011.11.011 Pansadoro, 2002, Long-term follow-up of G3T1 transitional cell carcinoma of the bladder treated with intravesical bacille Calmette-Guerin: 18-year experience, Urology, 59, 227, 10.1016/S0090-4295(01)01603-X Kim, 2019, Prognosis of carcinoma in situ according to the presence of papillary bladder tumors after bacillus Calmette-Guerin immunotherapy, J Cancer Res Clin Oncol, 145, 2131, 10.1007/s00432-019-02956-6 Piszczek, 2020, Clinical outcomes and survival differences between primary, secondary and concomitants carcinoma in situ of urinary bladder treated with BCG immunotherapy, Transl Androl Urol, 9, 1338, 10.21037/tau.2020.03.40 Jarow, 2015, Development of systemic and topical drugs to treat non-muscle invasive bladder cancer, Bladder Cancer, 1, 133, 10.3233/BLC-150016 Matulay, 2021, Contemporary outcomes of patients with nonmuscle-invasive bladder cancer treated with bacillus Calmette-Guerin: implications for clinical trial design, J Urol, 205, 1612, 10.1097/JU.0000000000001633 Nishiyama, 2018, Upper tract urothelial carcinoma following intravesical bacillus Calmette-Guerin therapy for nonmuscle-invasive bladder cancer: results from a multi-institutional retrospective study, Urol Oncol, 36, 306.e9, 10.1016/j.urolonc.2018.02.009 Tham, 2021, Intravesical high dose BCG Tokyo and low dose BCG Tokyo with GMCSF+IFNα induce systemic immunity in a murine orthotopic bladder cancer model, Biomedicines, 9, 1766, 10.3390/biomedicines9121766 Babjuk, 2022, European Association of Urology guidelines on non-muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ), Eur Urol, 81, 75, 10.1016/j.eururo.2021.08.010 Chang, 2016, Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline, J Urol, 196, 1021, 10.1016/j.juro.2016.06.049